(5R)-5-Propyloxolan-2-one
Common Name: |
(5R)-5-Propyloxolan-2-one |
IUPAC Name: |
(5R)-5-propyloxolan-2-one |
Molecular Formula: |
C9H17NO2 |
SMILES: |
CCCC1CCC(=O)O1 |
Inchi: |
1S/C7H12O2/c1-2-3-6-4-5-7(8)9-6/h6H,2-5H2,1H3/t6-/m1/s1 |
Inchi Key: |
VLSVVMPLPMNWBH-ZCFIWIBFSA-N |
Cas No: |
88270-38-6 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
0 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
171.24 |
Mass (g/mol) |
128.084 |
Molar Refractivity |
51.75 |
Net Charge |
|
HBD |
|
HBA |
2 |
Rt Bonds |
4 |
Rings |
1 |
TPSA |
29.54 |
Hetero Atoms |
2 |
Heavy Atoms |
12 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
226.00 to 227.00 |
Vapor Pressure (mmHg@25.00 °C) |
0.083 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.89 |
LogP |
1.492 |
iLOGP |
2.41 |
XLOGP3 |
2.13 |
WLOGP |
1.64 |
MLOGP |
1.41 |
ESOL Log S |
-1.98 |
ESOL Solubility (mg/ml) |
1.79 |
ESOL Solubility (mol/l) |
0.011 |
ESOL Class: esol_class |
Very soluble |
Ali Log S |
-2.38 |
Ali Solubility (mg/ml) |
0.71 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-1.83 |
Silicos-IT Solubility (mg/ml) |
2.51 |
Silicos-IT Solubility (mol/l) |
0.01 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-5.83 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.515 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
1.503 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |